Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. - Wikidata - awgldk - TriplyDB

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

http://www.wikidata.org/entity/Q34584163

about

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Axitinib for the management of metastatic renal cell carcinoma Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Axitinib in Metastatic Renal Cell Carcinoma Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma A synthetic dl-nordihydroguaiaretic acid (Nordy), inhibits angiogenesis, invasion and proliferation of glioma stem cells within a zebrafish xenotransplantation model Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Molecular diagnosis and therapy of kidney cancer.The genetic basis of kidney cancer: a metabolic disease Targeted therapies in renal cell cancer: recent developments in imaging Anti-VEGF Cancer Therapy in Nephrology Practice Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Sunitinib and other targeted therapies for renal cell carcinoma.Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Immunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis Future directions in renal cell carcinoma: 2011 and beyond Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

P2860

Q21183974-D7539AFB-ACD0-4C85-A542-2ACF4B08FA70 Q24606852-7F4C9738-1708-4357-BD07-50653680C473 Q24613720-97541836-A09A-49E5-AA8E-4A3E8F420DC8 Q26741201-85A1F3BC-6C33-411E-BF9A-D588A9F328C7 Q26751341-76D16F2C-EEE6-4A23-B394-5DBA2D8F790B Q26998017-579B52E4-EDF7-423E-98E0-5F7DF6B86407 Q27026961-345601FC-975A-428C-9473-01209096BE81 Q27028048-FC66F000-AF77-4697-B6BC-059738084C9E Q28538737-37E724E2-DCFB-4209-8399-5D66275FA43D Q30383438-280A5635-EC43-45E9-8D17-B483BEDEE75D Q30472042-EAC05192-2A1E-4A35-974A-90ADF7E029FE Q33400232-59C1E218-7C96-41CF-A39B-4858F77E9C5C Q33424379-7833344B-68D1-4EA5-A0AC-9F399FD98871 Q33554432-D614847B-0157-44AA-AA86-4318AFD36747 Q33555212-C233AB33-54D3-45F4-AB21-B9C88CD57987 Q33633424-A2AAF7D3-FC77-4B98-95E2-9A5C8F98D448 Q33708158-E09ECC5A-1EB0-458E-9D98-B5F9CCF3110E Q33918044-921E169B-C791-4889-BEEB-41A768294664 Q33997879-D77C1833-9541-46DA-9B30-F4E562A33665 Q34065685-4738CE61-F01D-4EB5-A7CE-C7C8847ED363 Q34087148-31DCFBDC-3613-4502-899E-696CDF7DD979 Q34088696-73BE4895-1BBC-4A92-B880-BBDF392B4AF9 Q34152125-C5C9DA17-0BA9-43D1-9BD8-E60D7D939DC8 Q34245458-C21E84C1-32ED-4446-B3F2-DC84F85CA0B9 Q34253081-A9834071-13AF-4D96-9FA4-29A29B594926 Q34421984-E42B05BF-E140-4DB0-9B1A-F9539B109BBF Q34504397-A36F9F17-49CF-4354-84D4-5DCEA5F3EE8A Q34554398-F924CB23-E01F-4B35-88F9-7EE5CF6D619E Q34616440-7D48FA61-9DBE-4314-9294-B52EED4CB31F Q34621802-46CC0A7E-A561-4E76-93C7-B6367AC075B4 Q34627163-F0380A9D-5072-4C42-82D6-870478C5F1D4 Q34627828-BB63AA8C-703F-4191-99F2-300B7543E125 Q34636002-52A441F8-DF95-4BD2-B7C7-5B772A158B06 Q34660154-6FC0CFC6-E9B6-4170-934B-D414E5D023C6 Q34661185-F69AD3B2-15D0-4033-A0F5-D82968C935C0 Q35052037-1EB6C05F-4B6B-44E0-8D82-6334C260D4C9 Q35118673-18A10DCF-E54E-417A-8F02-CB4DFC8F66BF Q35152107-4722BA07-D16C-4EF9-BA35-38D3CE3D0B41 Q35152565-4C122C73-9DE9-48BE-AC38-47C23740691E Q35187848-B9A0A935-4B3D-4319-9C6D-3B09742819D6

P2860

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

http://www.wikidata.org/entity/Q34584163

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Axitinib treatment in patients ...... cell cancer: a phase II study.

@ast

Axitinib treatment in patients ...... cell cancer: a phase II study.

@en

Axitinib treatment in patients ...... cell cancer: a phase II study.

@nl

type

label

Axitinib treatment in patients ...... cell cancer: a phase II study.

@ast

Axitinib treatment in patients ...... cell cancer: a phase II study.

@en

Axitinib treatment in patients ...... cell cancer: a phase II study.

@nl

prefLabel

Axitinib treatment in patients ...... cell cancer: a phase II study.

@ast

Axitinib treatment in patients ...... cell cancer: a phase II study.

@en

Axitinib treatment in patients ...... cell cancer: a phase II study.

@nl

P1433

Q34584163-9DE89089-456F-4380-B476-AAB43812CD4C

P1476

Q34584163-536C57E3-9637-4A8D-A008-C2452FCEB37C

P2093

Q34584163-081E8140-0827-4DE4-896A-F3B098DA39CF

Q34584163-0AE35F51-C521-453D-A431-0660F6F168B8

Q34584163-18660D0F-F6A5-407F-A229-E9B3D4B87954

Q34584163-1F243577-8234-4841-9AF2-A09AA41D3BB6

Q34584163-8AACE336-9C0B-4907-99BB-5D3DB7329D4E

Q34584163-ABBE33E6-DFB4-4AB4-8D4D-56FA6052701A

Q34584163-E3592BA5-8EA6-4A58-BEA0-3884793663B5

Q34584163-F2E2BFEA-0812-4179-B348-2549D79A04FE

Q34584163-F32090AA-35A0-48F6-B5BD-5165FA052AC6

Q34584163-F7BE1A8F-D6B1-416E-A5F0-69CE87D0CEAA

P304

Q34584163-F422DCDA-05CE-49BD-AECD-1FA6D22F28AA

P31

Q34584163-63033E8A-C4DC-44D2-9730-59D45C289CBD

P356

Q34584163-8C04509A-A454-4567-B574-AD00C27438E9

P433

Q34584163-AD35266A-E783-4714-86BF-8FD6082E7772

P478

Q34584163-8AD0B944-E4E5-4BED-87C3-DD57CC102F66

P50

Q34584163-DA9E7B8C-850B-4D27-96E5-26EB72FE6AB5

Q34584163-E162EC04-89E7-43AB-B370-06A9539AFED9

Q34584163-E48D3543-E8CB-4CCC-B6BE-B9CDAA1944BF

P577

Q34584163-0445A6C2-DD5E-4196-8095-61675173D2B2

P698

Q34584163-EAC337C5-1AEF-497B-A065-B621B48B1734

P921

Q34584163-91A3E1C7-CEEF-4A55-8EB1-58AAF748A209

P356

S1470-2045(07)70285-1

P1433

The Lancet Oncology

P1476

Axitinib treatment in patients ...... cell cancer: a phase II study.

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Gary R Hudes

http://www.w3.org/2001/XMLSchema#string

James Freddo

http://www.w3.org/2001/XMLSchema#string

Katherine F Liau

http://www.w3.org/2001/XMLSchema#string

M Dror Michaelson

http://www.w3.org/2001/XMLSchema#string

Oliver Bolte

http://www.w3.org/2001/XMLSchema#string

Paul Bycott

http://www.w3.org/2001/XMLSchema#string

Peter C Trask

http://www.w3.org/2001/XMLSchema#string

Ronald M Bukowski

http://www.w3.org/2001/XMLSchema#string

Sinil Kim

http://www.w3.org/2001/XMLSchema#string

P304

975-984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(07)70285-1

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17959415

http://www.w3.org/2001/XMLSchema#string

P921